AnaptysBio (NASDAQ:ANAB) Director John Schmid Sells 20,645 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director John Schmid sold 20,645 shares of the firm’s stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $56.11, for a total value of $1,158,390.95. Following the completion of the transaction, the director owned 31,622 shares of the company’s stock, valued at approximately $1,774,310.42. The trade was a 39.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

AnaptysBio Stock Up 1.7%

AnaptysBio stock opened at $57.68 on Friday. The stock has a 50-day moving average price of $56.08 and a 200 day moving average price of $44.42. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -110.92 and a beta of 0.40. AnaptysBio, Inc. has a 52 week low of $15.40 and a 52 week high of $68.39.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.69. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. The company had revenue of $108.25 million for the quarter, compared to the consensus estimate of $87.09 million. Research analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its board has authorized a share buyback program on Friday, March 27th that allows the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization allows the biotechnology company to reacquire up to 5,352,316.2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ANAB shares. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. UBS Group lifted their price objective on AnaptysBio from $70.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Wedbush boosted their price objective on AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Finally, Truist Financial upgraded shares of AnaptysBio to a “hold” rating in a research report on Wednesday, March 25th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $80.10.

Institutional Trading of AnaptysBio

A number of institutional investors and hedge funds have recently made changes to their positions in ANAB. Vanguard Group Inc. raised its stake in shares of AnaptysBio by 4.5% during the 4th quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock worth $74,855,000 after buying an additional 67,048 shares during the period. State Street Corp increased its holdings in AnaptysBio by 20.6% in the 4th quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock worth $51,072,000 after acquiring an additional 180,042 shares in the last quarter. Assenagon Asset Management S.A. raised its position in AnaptysBio by 4,852.7% during the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after acquiring an additional 822,975 shares during the period. 683 Capital Management LLC raised its position in AnaptysBio by 18.5% during the fourth quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock worth $31,420,000 after acquiring an additional 101,093 shares during the period. Finally, Affinity Asset Advisors LLC purchased a new position in AnaptysBio during the fourth quarter valued at $21,559,000.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.